Andrographolide activity on the cellular level has been documented well through a number of clinical studies.
The compound Andrographolide has been reported as a potential inhibitor of the main protease of SARS-COV-2 (Mpro) through in silico studies such as molecular docking, target analysis, toxicity prediction and ADME prediction in a reported published literature.
Andrographolide prevent spread as well as transmission of virus to neighboring cells by interfering with different cell signaling pathways1
Exhibits immunomodulatory effects by effectively enhancing cytotoxic T cells, natural killer (NK) cells, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC)2
Andrographolide increase the survival rate, diminish lung pathology, decrease the virus loads and the inflammatory cytokines expression induced by H1N1 infection3
Andrographolide is also reported to display immunostimulatory action by efficaciously increasingCD4+ and CD8+ cells population.
Bio-immuneTM, the bio-enhanced Andrographolide, is also proven to be a potential inhibitor, inhibiting the replication of SARS-COV-2 virus.
In-vitro Anti-viral study,shows that >99% inhibition of SARS –CoV-2 virus replicationby Bio-immune.